
Celltrion Plans to Develop Tests to Determine ADA Levels in Blood
A study shows high levels of ADAs to infliximab at the beginning of treatment were associated with a poor response later on.
Celltrion Healthcare says it is committed to developing laboratory tests that will determine both drug and antidrug antibody (ADA) levels in the blood, the company said in a July 5, 2016
This commitment may be partially the result of a
“Biologics and biosimilars tested with advanced analytical methods to assess drug and ADA levels could be used for developing tailored treatments, said Man Hoon Kim, president of Celltrion Healthcare, in a press announcement. “Celltrion is fully committed to support this type of research to develop affordable laboratory tests, or kits, for routine monitoring that allows personalized infliximab treatment according to the disease status of individual patients.”
The company recently extended its Remsima studies, PLANETRA AND PLANETAS, up to 102 weeks. The extension studies indicated Remsima was effective over two years and that the efficacy, safety, and immunogenicity of Remsima and the reference product were comparable, Celltrion says.
FDA
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.